Learn more →
Back to Expert Scholars
Translational Medicine / 转化医学Ovarian Cancer

Jonathan Ledermann

乔纳森·莱德曼

MD, FRCP

🏢University College London Cancer Institute(伦敦大学学院癌症研究所)🌐UK

Emeritus Professor of Medical Oncology; Honorary Consultant Medical Oncologist肿瘤内科学荣誉教授;荣誉顾问肿瘤内科医生

68
h-index
2
Key Papers
3
Awards
2
Key Contributions

👥Biography 个人简介

Jonathan Ledermann, MD, FRCP is an Emeritus Professor of Medical Oncology at UCL Cancer Institute with over three decades of leadership in ovarian cancer clinical trials. He led Study 19 (the first olaparib maintenance trial) and co-led SOLO-2, foundational studies that proved PARP inhibitor maintenance in platinum-sensitive ovarian cancer.

Share:

🧪Research Fields 研究领域

Ovarian Cancer卵巢癌
PARP InhibitorsPARP抑制剂
Olaparib奥拉帕尼
Platinum-Sensitive Recurrence铂敏感复发
Phase III Gynecologic Oncology TrialsIII期妇科肿瘤试验

🎓Key Contributions 主要贡献

Study 19: First Olaparib Maintenance Proof of Concept

Principal investigator of Study 19, the landmark phase II trial that first demonstrated olaparib maintenance therapy significantly improved progression-free survival in platinum-sensitive recurrent ovarian cancer, particularly in BRCA-mutated patients.

SOLO-2 Olaparib Phase III Confirmation

Co-led SOLO-2, the confirmatory phase III trial establishing olaparib maintenance as standard of care for BRCA-mutated, platinum-sensitive recurrent ovarian cancer.

Representative Works 代表性著作

[1]

Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer (Study 19)

New England Journal of Medicine (2012)

First randomized trial demonstrating olaparib maintenance significantly prolonged progression-free survival, with greatest benefit in BRCA-mutated patients, establishing the PARP inhibitor maintenance concept.

[2]

Olaparib tablets as maintenance therapy in patients with BRCA1/2-mutated advanced ovarian cancer (SOLO-2)

The Lancet Oncology (2017)

Confirmatory phase III trial establishing olaparib tablet formulation maintenance as standard care in BRCA-mutated, platinum-sensitive recurrent ovarian cancer.

🏆Awards & Recognition 奖项与荣誉

🏆British Gynaecological Cancer Society Lifetime Achievement Award
🏆ESGO Distinguished Service Award
🏆Royal College of Physicians Fellowship (FRCP)

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 乔纳森·莱德曼 的研究动态

Follow Jonathan Ledermann's research updates

留下邮箱,当我们发布与 Jonathan Ledermann(University College London Cancer Institute)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment